Rare disease-focused Prosensa brings in US investor in new €23 million round
This article was originally published in Scrip
Executive Summary
Prosensa, the Dutch firm focused on RNA-modulating therapies for rare diseases, has raised €23 million in new venture capital funding. The round was led by new investor New Enterprise Associates and included existing investors Abingworth, Life Sciences Partners, Gimv, Idinvest Partners and MedSciences Capital.